Domiziana Santucci

Dr. Domiziana Santucci

Campus Bio Medico University Hospital, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2021 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ACAlessandro Calabrese
Alessandro Calabrese
DSDomiziana Santucci
Domiziana Santucci
RLRoberta Landi
Roberta Landi
Bruno Beomonte ZobelBruno Beomonte Zobel
Bruno Beomonte Zobel
EFEliodoro Faiella
Eliodoro Faiella
CFCarlo de Felice
Carlo de Felice

14 October 2020 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
MSMariano Scaglione
Mariano Scaglione
MGMichele Galluzzo
Michele Galluzzo
DSDomiziana Santucci
Domiziana Santucci
MTMargherita Trinci
Margherita Trinci
LMLaura Messina
Laura Messina
BZBruno Beomonte Zobel
Bruno Beomonte Zobel

29 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
GPGiuseppe Francesco Papalia
Giuseppe Francesco Papalia
PBPaolo Brigato
Paolo Brigato
LSLuisana Sisca
Luisana Sisca
GMGirolamo Maltese
Girolamo Maltese
EFEliodoro Faiella
Eliodoro Faiella
VDVincenzo Denaro
Vincenzo Denaro
Background: Metastasis commonly occur in the bone tissue. Artificial intelligence (AI) has become increasingly prevalent in the medical sector as support in decision-making, diagnosis, and treatment processes. The objective of this systematic review was to assess the reliability of AI systems in clinical, radiological, and pathological aspects of bone metastases. Methods: We included studies that evaluated the use of AI applications in patients affected by bone metastases. Two reviewers performed a digital search on 31 December 2023 on PubMed, Scopus, and Cochrane library and extracted authors, AI method, interest area, main modalities used, and main objectives from the included studies. Results: We included 59 studies that analyzed the contribution of computational intelligence in diagnosing or forecasting outcomes in patients with bone metastasis. Six studies were specific for spine metastasis. The study involved nuclear medicine (44.1%), clinical research (28.8%), radiology (20.4%), or molecular biology (6.8%). When a primary tumor was reported, prostate cancer was the most common, followed by lung, breast, and kidney. Conclusions: Appropriately trained AI models may be very useful in merging information to achieve an overall improved diagnostic accuracy and treatment for metastasis in the bone. Nevertheless, there are still concerns with the use of AI systems in medical settings. Ethical considerations and legal issues must be addressed to facilitate the safe and regulated adoption of AI technologies. The limitations of the study comprise a stronger emphasis on early detection rather than tumor management and prognosis as well as a high heterogeneity for type of tumor, AI technology and radiological techniques, pathology, or laboratory samples involved.

6 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DSDomiziana Santucci
Domiziana Santucci
EFEliodoro Faiella
Eliodoro Faiella
ECErmanno Cordelli
Ermanno Cordelli
RSRosa Sicilia
Rosa Sicilia
CFCarlo de Felice
Carlo de Felice
PSPaolo Soda
Paolo Soda
Background: axillary lymph node (LN) status is one of the main breast cancer prognostic factors and it is currently defined by invasive procedures. The aim of this study is to predict LN metastasis combining MRI radiomics features with primary breast tumor histological features and patients’ clinical data. Methods: 99 lesions on pre-treatment contrasted 3T-MRI (DCE). All patients had a histologically proven invasive breast cancer and defined LN status. Patients’ clinical data and tumor histological analysis were previously collected. For each tumor lesion, a semi-automatic segmentation was performed, using the second phase of DCE-MRI. Each segmentation was optimized using a convex-hull algorithm. In addition to the 14 semantics features and a feature ROI volume/convex-hull volume, 242 other quantitative features were extracted. A wrapper selection method selected the 15 most prognostic features (14 quantitative, 1 semantic), used to train the final learning model. The classifier used was the Random Forest. Results: the AUC-classifier was 0.856 (label = positive or negative). The contribution of each feature group was lower performance than the full signature. Conclusions: the combination of patient clinical, histological and radiomics features of primary breast cancer can accurately predict LN status in a non-invasive way.

29 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
VCVeronica Celli
Veronica Celli
MGMichele Guerreri
Michele Guerreri
APAngelina Pernazza
Angelina Pernazza
ICIlaria Cuccu
Ilaria Cuccu
IPInnocenza Palaia
Innocenza Palaia
Lucia ManganaroLucia Manganaro
Lucia Manganaro
High- and low-risk endometrial carcinoma (EC) differ in whether or not a lymphadenectomy is performed. We aimed to develop MRI-based radio-genomic models able to preoperatively assess lymph-vascular space invasion (LVSI) and discriminate between low- and high-risk EC according to the ESMO-ESGO-ESTRO 2020 guidelines, which include molecular risk classification proposed by “ProMisE”. This is a retrospective, multicentric study that included 64 women with EC who underwent 3T-MRI before a hysterectomy. Radiomics features were extracted from T2WI images and apparent diffusion coefficient maps (ADC) after manual segmentation of the gross tumor volume. We constructed a multiple logistic regression approach from the most relevant radiomic features to distinguish between low- and high-risk classes under the ESMO-ESGO-ESTRO 2020 guidelines. A similar approach was taken to assess LVSI. Model diagnostic performance was assessed via ROC curves, accuracy, sensitivity and specificity on training and test sets. The LVSI predictive model used a single feature from ADC as a predictor; the risk class model used two features as predictors from both ADC and T2WI. The low-risk predictive model showed an AUC of 0.74 with an accuracy, sensitivity, and specificity of 0.74, 0.76, 0.94; the LVSI model showed an AUC of 0.59 with an accuracy, sensitivity, and specificity of 0.60, 0.50, 0.61. MRI-based radio-genomic models are useful for preoperative EC risk stratification and may facilitate therapeutic management.

EFEliodoro Faiella
Eliodoro Faiella
DSDomiziana Santucci
Domiziana Santucci
ACAlessandro Calabrese
Alessandro Calabrese
FRFabrizio Russo
Fabrizio Russo
Gianluca VadalàGianluca Vadalà
Gianluca Vadalà
VDVincenzo Denaro
Vincenzo Denaro
(1) Background: The purpose of this review is to study the role of radiomics as a supporting tool in predicting bone disease status, differentiating benign from malignant bone lesions, and characterizing malignant bone lesions. (2) Methods: Two reviewers conducted the literature search independently. Thirteen articles on radiomics as a decision support tool for bone lesions were selected. The quality of the methodology was evaluated according to the radiomics quality score (RQS). (3) Results: All studies were published between 2018 and 2021 and were retrospective in design. Eleven (85%) studies were MRI-based, and two (15%) were CT-based. The sample size was <200 patients for all studies. There is significant heterogeneity in the literature, as evidenced by the relatively low RQS value (average score = 22.6%). There is not a homogeneous protocol used for MRI sequences among the different studies, although the highest predictive ability was always obtained in T2W-FS. Six articles (46%) reported on the potential application of the model in a clinical setting with a decision curve analysis (DCA). (4) Conclusions: Despite the variability in the radiomics method application, the similarity of results and conclusions observed is encouraging. Substantial limits were found; prospective and multicentric studies are needed to affirm the role of radiomics as a supporting tool.